Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations.
Athyrium advises funds with over $4.5 billion of committed capital.
Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations.
Athyrium advises funds with over $4.5 billion of committed capital.
Basilea Announces CHF 75 Million Senior Secured Loan Agreement with Athyrium
RVL Pharmaceuticals plc Announces Insider and Athyrium-Led Financing
uMotif Expands Leadership Team to Support Growth in US and EU Markets
U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® for the Treatment of Cervical Dystonia
Syneos Health and uMotif Partner to Deliver Patient-centric eClinical Platform
Humana and Longevity Health Partner to Expand Access to Special Needs Plans for Medicare Beneficiaries
Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection